Show simple item record

dc.contributor.authorLuck, J.N.
dc.contributor.authorTettelin, H.
dc.contributor.authorOrihuela, C.J.
dc.date.accessioned2021-02-08T20:13:21Z
dc.date.available2021-02-08T20:13:21Z
dc.date.issued2020-12-23
dc.identifier.urihttp://hdl.handle.net/10713/14526
dc.description.abstractCapsular polysaccharide (CPS), which surrounds the bacteria, is one of the most significant and multifaceted contributors to Streptococcus pneumoniae virulence. Capsule prevents entrapment in mucus during colonization, traps water to protect against desiccation, can serve as an energy reserve, and protects the bacterium against complement-mediated opsonization and immune cell phagocytosis. To date, 100 biochemically and serologically distinct capsule types have been identified for S. pneumoniae; 20 to 30 of which have well-defined propensity to cause opportunistic human infection. Among these, serotype 3 is perhaps the most problematic as serotype 3 infections are characterized as having severe clinical manifestations including empyema, bacteremia, cardiotoxicity, and meningitis; consequently, with a fatality rate of 30%–47%. Moreover, serotype 3 resists antibody-mediated clearance despite its inclusion in the current 13-valent conjugate vaccine formulation. This review covers the role of capsule in pneumococcal pathogenesis and the importance of serotype 3 on human disease. We discuss how serotype 3 capsule synthesis and presentation on the bacterial surface is distinct from other serotypes, the biochemical and physiological properties of this capsule type that facilitate its ability to cause disease, and why existing vaccines are unable to confer protection. We conclude with discussion of the clonal properties of serotype 3 and how these have changed since introduction of the 13-valent vaccine in 2000. Copyright Copyright Copyright 2020 Luck, Tettelin and Orihuela.en_US
dc.description.sponsorshipHT and CJO received grant support from NIH grants AI114800 and AI146149.en_US
dc.description.urihttps://doi.org/10.3389/fcimb.2020.613287en_US
dc.language.isoen_USen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Cellular and Infection Microbiology
dc.subjectcapsule productionen_US
dc.subjectinvasive pneumococcal diseaseen_US
dc.subjectserotype 3en_US
dc.subjectStreptococcus pneumoniaeen_US
dc.subjectsynthase-dependent pathwayen_US
dc.subjectvaccine escapeen_US
dc.subjectwzy-dependent pathwayen_US
dc.titleSugar-Coated Killer: Serotype 3 Pneumococcal Diseaseen_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fcimb.2020.613287
dc.identifier.pmid33425786


This item appears in the following Collection(s)

Show simple item record